Drug Delivery Systems--Fifth US-Japan Symposium. 12-17 December 1999, Lahaina, Hawaii.

IDrugs

Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Alberta T6G 2N8, Edmonton, Canada.

Published: March 2000

The field of drug delivery is moving rapidly from the more efficacious delivery of 'old' drugs, to the delivery of therapeutic peptides, proteins, oligonucleotides and genes. Liposomes, polymers, microbubbles, nanoparticles, wafers and chips are the jargon, and entrepreneurialism is the prevailing force. Indeed, the scientific spirit is overwhelmed by the push to market, as fledgling companies compete or collaborate with the established pharma industry in converting concepts into profits. The 'Holy Grail' is a slice of the multi-billion dollar global market for these specialized, high-tech products.

Download full-text PDF

Source

Publication Analysis

Top Keywords

drug delivery
8
delivery systems--fifth
4
systems--fifth us-japan
4
us-japan symposium
4
symposium 12-17
4
12-17 december
4
december 1999
4
1999 lahaina
4
lahaina hawaii
4
hawaii field
4

Similar Publications

With precise control of smart materials deformation in time dimension, doctors can customize orthopedic implants. This review focuses on the advances of 4D printing technology in orthopedics, including its applications in bone repair and reconstruction, personalized treatment, and drug delivery. 4D printing enables the creation of bionic scaffolds and fixation devices for bone repair, customized implants matching patients' conditions for personalized treatment, and specific carriers for accurate drug release and delivery, which together contribute to accelerating bone healing, providing exclusive treatments, enhancing therapeutic effects and reducing side effects, thus helping improve orthopedic medicine.

View Article and Find Full Text PDF

Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due to severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs).

View Article and Find Full Text PDF

The hypertension patient population has doubled since 1990, affecting 1.3 billion globally and >75% live in low-and middle-income countries. Angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) are the most prescribed drugs (>160 million times in the US), but mortality increased >30% since 1990s globally.

View Article and Find Full Text PDF

Barcoded screening identifies nanocarriers for protein delivery to kidney.

Nat Commun

January 2025

School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, P.R. China.

Targeted protein delivery with nanocarriers holds significant potential to enhance therapeutic outcomes by precisely directing proteins to specific organs or tissues. However, the complex interactions between nanocarriers and the biological environment pose considerable challenges in designing effective targeted delivery vehicles. In this study, we address this challenge by leveraging DNA-barcoded high-throughput screening.

View Article and Find Full Text PDF

Little is known about how exclusive e-cigarette use affects exosomal microRNA (miRNA) expression, which is crucial in inflammation and disease processes like cancer. We compared exosomal miRNA profiles between exclusive e-cigarette users and non-users. We used plasma samples from 15 exclusive e-cigarette users and 15 non-users from the Population Assessment of Tobacco and Health (PATH) Wave 1 study (2013-2014) and sequenced miRNAs with Illumina NextSeq 500/550.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!